TP53 and cancer: However, considering that only a subset of cancer patients (~20–50%) carrying TP53 somatic mutations have detectable p53-AAbs, genetic variants in TP53 alone are probably not sufficient to trigger the p53-AAbs secretion, but mutations of p53 regulators and non-mutative pathways are probably engaged as well [9].